Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders

• 收藏
• 分享

专利权人:

Simon Green;Ian Fleming;Sheelagh Frame

发明人:

Simon Green,Sheelagh Frame,Ian Fleming

申请号：

US12573358

公开号：

US09173938B2

申请日:

2009.10.05

申请国别(地区):

US

年份:

2015

代理人:

摘要：

The present invention relates to combination comprising (i) an ErbB inhibitor； and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine； (b) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol； (c) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol； and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol.Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising combinations according to the invention, and methods of treatment using the same.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/